276 related articles for article (PubMed ID: 21211672)
1. [Cardiac manifestations of Anderson-Fabry disease and efficacy of enzyme replacement therapy].
Hagège A
Rev Med Interne; 2010 Dec; 31 Suppl 2():S238-42. PubMed ID: 21211672
[TBL] [Abstract][Full Text] [Related]
2. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
[TBL] [Abstract][Full Text] [Related]
3. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
[TBL] [Abstract][Full Text] [Related]
4. [Cardiological follow-up in patients with Fabry disease].
Pieruzzi F; Pieroni M; Chimenti C; Frustaci A; Sarais C; Cecchi F;
G Ital Cardiol (Rome); 2010; 11(7-8):566-72. PubMed ID: 21033333
[TBL] [Abstract][Full Text] [Related]
5. Fabry disease and the heart: an overview of the natural history and the effect of enzyme replacement therapy.
Shah JS; Elliott PM
Acta Paediatr Suppl; 2005 Mar; 94(447):11-4; discussion 9-10. PubMed ID: 15895705
[TBL] [Abstract][Full Text] [Related]
6. Cardiac Fabry's disease: an unusual cause of left ventricular hypertrophy.
Nunes JP; Costa O; Faria Mdo S; Almeida PB; Lacerda L
Nat Clin Pract Cardiovasc Med; 2007 Nov; 4(11):630-3. PubMed ID: 17957210
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Effects of Enzyme Replacement Therapy for Anderson-Fabry Disease.
Tsujiuchi M; Ebato M; Maezawa H; Mizukami T; Nogi A; Ikeda N; Iso Y; Suzuki H
Int Heart J; 2019 Jan; 60(1):208-214. PubMed ID: 30464119
[TBL] [Abstract][Full Text] [Related]
8. Anderson-Fabry disease and the heart.
O'Mahony C; Elliott P
Prog Cardiovasc Dis; 2010; 52(4):326-35. PubMed ID: 20109602
[TBL] [Abstract][Full Text] [Related]
9. The heart in Anderson Fabry disease.
Kampmann C; Wiethoff CM; Perrot A; Beck M; Dietz R; Osterziel KJ
Z Kardiol; 2002 Oct; 91(10):786-95. PubMed ID: 12395219
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease.
Talbot AS; Lewis NT; Nicholls KM
Heart; 2015 Feb; 101(4):287-93. PubMed ID: 25381325
[TBL] [Abstract][Full Text] [Related]
11. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
12. Fabry disease presenting as apical left ventricular hypertrophy in a patient carrying the missense mutation R118C.
Caetano F; Botelho A; Mota P; Silva J; Leitão Marques A
Rev Port Cardiol; 2014 Mar; 33(3):183.e1-5. PubMed ID: 24661928
[TBL] [Abstract][Full Text] [Related]
13. Fabry disease in cardiology practice: Literature review and expert point of view.
Hagège A; Réant P; Habib G; Damy T; Barone-Rochette G; Soulat G; Donal E; Germain DP
Arch Cardiovasc Dis; 2019 Apr; 112(4):278-287. PubMed ID: 30826269
[TBL] [Abstract][Full Text] [Related]
14. Fabry disease and the heart.
Seydelmann N; Wanner C; Störk S; Ertl G; Weidemann F
Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):195-204. PubMed ID: 25987173
[TBL] [Abstract][Full Text] [Related]
15. Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy.
Maron MS; Xin W; Sims KB; Butler R; Haas TS; Rowin EJ; Desnick RJ; Maron BJ
Am J Med; 2018 Feb; 131(2):200.e1-200.e8. PubMed ID: 28943383
[TBL] [Abstract][Full Text] [Related]
16. Fabry disease.
Yuasa T; Takenaka T; Higuchi K; Uchiyama N; Horizoe Y; Cyaen H; Mizukami N; Takasaki K; Kisanuki A; Miyata M; Ohishi M
J Echocardiogr; 2017 Dec; 15(4):151-157. PubMed ID: 28674962
[TBL] [Abstract][Full Text] [Related]
17. Cardiac manifestations of Fabry's disease: a story of mother and son.
Moses H; Yarnoz MJ; Guglin M
Congest Heart Fail; 2009; 15(2):93-5. PubMed ID: 19379456
[No Abstract] [Full Text] [Related]
18. Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy.
Kovacevic-Preradovic T; Zuber M; Attenhofer Jost CH; Widmer U; Seifert B; Schulthess G; Fischer A; Jenni R
Eur J Echocardiogr; 2008 Nov; 9(6):729-35. PubMed ID: 18490303
[TBL] [Abstract][Full Text] [Related]
19. Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study.
Madsen CV; Bundgaard H; Rasmussen ÅK; Sørensen SS; Petersen JH; Køber L; Feldt-Rasmussen U; Petri H
Scand Cardiovasc J; 2017 Aug; 51(4):207-216. PubMed ID: 28545342
[TBL] [Abstract][Full Text] [Related]
20. Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.
Kim JH; Lee BH; Hyang Cho J; Kang E; Choi JH; Kim GH; Yoo HW
J Hum Genet; 2016 Nov; 61(11):923-929. PubMed ID: 27334365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
